Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Yeast Models Of Phosphomannomutase 2 Deficiency, A Congenital Disorder Of Glycosylation

View ORCID ProfileJessica P. Lao, Nina DiPrimio, Madeleine Prangley, Feba S. Sam, Joshua D. Mast, Ethan O. Perlstein
doi: https://doi.org/10.1101/414862
Jessica P. Lao
1Perlara PBC, 6000 Shoreline Court, South San Francisco, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jessica P. Lao
Nina DiPrimio
1Perlara PBC, 6000 Shoreline Court, South San Francisco, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madeleine Prangley
1Perlara PBC, 6000 Shoreline Court, South San Francisco, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Feba S. Sam
1Perlara PBC, 6000 Shoreline Court, South San Francisco, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua D. Mast
1Perlara PBC, 6000 Shoreline Court, South San Francisco, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ethan O. Perlstein
1Perlara PBC, 6000 Shoreline Court, South San Francisco, California USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Phosphomannomutase 2 Deficiency (PMM2-CDG) is the most common monogenic congenital disorder of glycosylation (CDG) affecting at least 800 patients globally. PMM2 orthologs are present in model organisms, including the budding yeast Saccharomyces cerevisiae gene SEC53. Here we describe conserved genotype-phenotype relationships across yeast and human patients between five PMM2 loss-of-function missense mutations and their orthologous SEC53 mutations. These alleles range in severity from folding defective (hypomorph) to dimerization defective (severe hypomorph) to catalytic dead (null). We included the first and second most common missense mutations – R141H, F119L respectively– and the most common compound heterozygote genotype – PMM2R141H/F119L – observed in PMM2-CDG patients. Each mutation described is expressed in haploid as well as homozygous and heterozygous diploid yeast cells at varying protein expression levels as either SEC53 protein variants or PMM2 protein variants. We developed a 384-well-plate, growth-based assay for use in a screen of the 2,560-compound Microsource Spectrum library of approved drugs, experimental drugs, tool compounds and natural products. We identified three compounds that suppress growth defects of SEC53 variants, F126L and V238M, based on the biochemical defect of the allele, protein abundance or ploidy. The rare PMM2 E139K protein variant is fully functional in yeast cells, suggesting that its pathogenicity in humans is due to the underlying DNA mutation that results in skipping of exon 5 and a nonfunctional truncated protein. Together, these results demonstrate that yeast models can be used to characterize known and novel PMM2 patient alleles in quantitative growth and enzymatic activity assays, and used as patient avatars for PMM2-CDG drug screens yielding compounds that could be rapidly cross-validated in zebrafish, rodent and human organoid models.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 14, 2018.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Yeast Models Of Phosphomannomutase 2 Deficiency, A Congenital Disorder Of Glycosylation
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Yeast Models Of Phosphomannomutase 2 Deficiency, A Congenital Disorder Of Glycosylation
Jessica P. Lao, Nina DiPrimio, Madeleine Prangley, Feba S. Sam, Joshua D. Mast, Ethan O. Perlstein
bioRxiv 414862; doi: https://doi.org/10.1101/414862
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Yeast Models Of Phosphomannomutase 2 Deficiency, A Congenital Disorder Of Glycosylation
Jessica P. Lao, Nina DiPrimio, Madeleine Prangley, Feba S. Sam, Joshua D. Mast, Ethan O. Perlstein
bioRxiv 414862; doi: https://doi.org/10.1101/414862

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetics
Subject Areas
All Articles
  • Animal Behavior and Cognition (4234)
  • Biochemistry (9135)
  • Bioengineering (6784)
  • Bioinformatics (23999)
  • Biophysics (12129)
  • Cancer Biology (9534)
  • Cell Biology (13777)
  • Clinical Trials (138)
  • Developmental Biology (7635)
  • Ecology (11701)
  • Epidemiology (2066)
  • Evolutionary Biology (15512)
  • Genetics (10644)
  • Genomics (14325)
  • Immunology (9482)
  • Microbiology (22839)
  • Molecular Biology (9090)
  • Neuroscience (48989)
  • Paleontology (355)
  • Pathology (1482)
  • Pharmacology and Toxicology (2570)
  • Physiology (3845)
  • Plant Biology (8331)
  • Scientific Communication and Education (1471)
  • Synthetic Biology (2296)
  • Systems Biology (6190)
  • Zoology (1301)